Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Rydapt receives NICE recomendation to treat agressive systemic mastocytosis – Novartis

Written by | 30 Aug 2021 | Haematology

Novartis welcomed the news that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending Rydapt (midostaurin) for the treatment of aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms or mast cell leukaemia (nb – collectively called AdvSM).

Midostaurin is the first and only licensed treatment for AdvSM in the UK and has been shown to provide therapeutic benefits to adults with the disease.

AdvSM affects between 1 in 10,000 – 30,000 people. The life-threating blood disorder is characterised by uncontrolled growth and accumulation of mast cells – mediators of allergic responses – in one or more organs. These cells accumulate in such high quantities that they begin to cause organ damage. The wide-ranging symptoms of the disease can have a devastating impact on an individual’s quality of life. Symptoms include itching, fever, abdominal pain, nausea and vomiting. Until today, patients in the UK could only access drugs to treat their symptoms, not targeted therapy that inhibits KIT signalling, cell proliferation and histamine release, and induce apoptosis in mast cells.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.